Kaplan Fox Announces a Securities Class Action Against Beta Bionics, Inc. (NASDAQ: BBNX) – Lead Plaintiff Deadline is November 3, 2026GlobeNewsWire · 52 min ago
What Should Beta Bionics, Inc. Investors Know After 37% Stock Drop? The Law Offices of Frank R.PRNewsWire · 2 hr ago
BBNX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026Newsfile Corp · 3 hr ago
BBNX Deadline Alert: Levi & Korsinsky Reminds Beta Bionics, Inc. (BBNX) Investors of Securities Class Action Deadline on November 3, 2026GlobeNewsWire · 3 hr ago
BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitPRNewsWire · 3 hr ago
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action LawsuitGlobe News Wire · 5 hr agoBeta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$0.58 | -$0.53 | Beat |
| Apr 21, 2026 | -$0.53 | -$0.49 | Beat |
| Feb 17, 2026 | -$0.42 | -$0.30 | Beat |
| Oct 28, 2025 | -$0.45 | -$0.33 | Beat |
| Jul 29, 2025 | -$0.51 | -$0.39 | Beat |
| May 6, 2025 | -$0.51 | -$0.52 | Miss |